jackie.vuistiner

CUTISS to participate in Jefferies London Healthcare Conference 2022

Switzerland, 7 November 2022 – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced that the company is invited to the upcoming Jefferies London Healthcare Conference, taking place November 15 – 17, 2022. Dr Daniela Marino, Chief Executive Officer and co-founder at CUTISS, will attend the conference …

CUTISS to participate in Jefferies London Healthcare Conference 2022 Read More »

Swiss RTS television reportage on innovation and denovoCast

More than a year since CUTISS announced the world’s first machine to bioengineer human skin, the news continues to generate interest and excitement. As part of their program focused on Swiss innovation, the broadcaster RTS (Neuchatel) visited CUTISS and CSEM who helped develop the denovoCast machine, to find out how automation can scale-up the production …

Swiss RTS television reportage on innovation and denovoCast Read More »

Tribune de Côte d’Azur reports on CUTISS Innovation

The Tribune de Côte d’Azur covered the first ‘Impact Awards’ 2022, a jury-led competition organized by Team Côte d’Azur that recognizes leading companies of the local economic ecosystem. CUTISS Innovation, our French subsidiary, was honored to win the ‘Innovation’ trophy for continued innovation and research into regenerative medicine and skin pigmentation. Our director Cécile Cousin was …

Tribune de Côte d’Azur reports on CUTISS Innovation Read More »

CUTISS Innovation wins Impact Award 2022

CUTISS Innovation, our French subsidiary, was honored to win the ‘Innovation’ trophy for continued innovation and research into regenerative medicine and skin pigmentation. This was part of the first annual Impact Awards, a jury-led competition organized by Team Côte d’Azur that recognizes leading companies of the local economic ecosystem. Our director Cécile Cousin was there …

CUTISS Innovation wins Impact Award 2022 Read More »

Recruitment completed for denovoSkin Phase 2 clinical trial, adult & adolescent patients

PRESS RELEASE CUTISS completes recruitment for denovoSkin™ Phase 2 clinical trial in adult and adolescent burn patients Switzerland, 7 September 2022 – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced the completion of recruitment for the Phase 2 clinical trial of its lead product denovoSkin™ …

Recruitment completed for denovoSkin Phase 2 clinical trial, adult & adolescent patients Read More »

CUTISS granted European patent for skin tissue graft

CUTISS is pleased to announce that a tissue graft patent has been granted by the European Patent Office for the personalized bioengineered human skin tissue therapy developed by CUTISS. The patent (3174563) has been granted pursuant to Article 97(1) EPC to University of Zurich (UZH) where the founders of CUTISS worked at the time of …

CUTISS granted European patent for skin tissue graft Read More »

Scroll to Top

Newsletter

Would you like to contact us as a journalist?

©WyssZurich

This website uses cookies to ensure you get the best experience on our website.